



## Ovarian Cancer

### Syndicated Thought Leader Insight

## *Thought Leader Insight & Analysis Report* Ovarian Cancer Q1 2010

<b>Therapeutic Class:</b>	Oncology
<b>Focus Area:</b>	Ovarian Cancer
<b>Specialty/Location:</b>	Oncologists/U.S.
<b>Number of Interviews:</b>	7
<b>Number of Pages:</b>	146
<b>Publication Date:</b>	February 2010
<b>Principal Authors:</b>	Kim Grant Tricia L. Hanlon Jeffrey D. Berk, Ph.D., MBA
<b>Product Code:</b>	MHOOCQ110-23
<b>Pricing:</b>	\$7,500
<b>Order Info:</b>	www.medpredict.com or call (513) 271-1924

**Abstract:** Ovarian cancer is only one tenth as common as breast cancer, but the mortality associated with ovarian cancer is higher. There are 250,000 new cases diagnosed each year in the US, and at least 15,000 women die each year in the US from ovarian cancer. While the 5-year survival for non-metastatic disease is 75%, only 20% of metastatic patients live this long. Thus there is an urgent unmet need for improved treatment strategies for ovarian cancer.

This report summarizes the perspectives of 7 highly regarded ovarian cancer specialists (all US-based). In this report they provide their opinions on standards of care today and their expectations for experimental therapeutics. The “next big thing” will be Avastin, so the Panel evaluates inhibitors of PARP and mTOR/PI3K/AKT (& MEK) in a world where oncologists have moved from platinum doublets to a triplet containing bevacizumab, carboplatin and (paclitaxel / gemcitabine / doxorubicin). The Panel identifies strengths and weaknesses for lead compounds amongst the most important mechanisms in development for ovarian cancer.

**Pharmacotherapies/Companies Discussed in This Report (Alphabetical by Target):**

Angiogenesis inhibitors (VEGF / PDGF /FGF / VDA)

Avastin; bevacizumab (Genentech)  
aflibercept; VEGF Trap (Sanofi-Aventis)  
Nexavar; sorafenib (Bayer-Schering/Onyx), Sutent; sunitinib (Pfizer)  
Recentin; cediranib (AstraZeneca)  
brivanib (Bristol-Myers Squibb)  
Votrient; pazopanib (GlaxoSmithKline)  
BIBF-1120 (Boehringer Ingelheim)  
fosbretabulin; CA4P (OxiGene)  
ASA404 (Novartis)  
AMG-386 (Amgen)

EGFR

Tarceva; erlotinib (OSI Pharmaceuticals / Genentech)

alpha-folate receptor inhibitors

Farletuzumab (Morphotek /Eisai)  
EC-145 (Endocyte)

Hedgehog Pathway Inhibitors

GDC-0449 (Genentech)  
IPI-504; cyclopamine (Infinity)

Immunology Approaches

abagovomab (Menarini)

MEK

AZD-6244; ARRY-142886 (AstraZeneca)

mTOR / PI3K / AKT

perifosine; KRX-0401 (Keryx)  
Torisel; temsirolimus (Pfizer)  
Afinitor; everolimus (Novartis)  
MK-2206 (Merck) / AZD-6244 (AstraZeneca)  
AZD8055 (AstraZeneca)  
PI3K

PARP

olaparib; AZD2281 (AstraZeneca)  
BSI201 (BiPar Sciences / Sanofi-Aventis)  
ABT-888 (Abbott)  
MK-4827 (Merck), AG014699 (Pfizer)

Platinum

cisplatin, carboplatin, Eloxatin; oxaliplatin  
mitaplatin (Massachusetts Institute of Technology)

Src

Sprycel; dasatinib (Bristol-Myers Squibb)

Superoxide

Yondelis; trabectedin (Ortho; Johnson & Johnson / Zeltia)

Taxane / Epothilone

Taxol; paclitaxel (Bristol-Myers Squibb)  
Abraxane (Abraxis)  
Xyotax; a.k.a. Opaxio (Cell Therapeutics)  
patupilone (Novartis)

# Table of Contents

Executive Summary .....	4
Top-Ten Report Highlights.....	6
Key Findings.....	16
Ovarian Cancer Standards of Care / Unmet Needs.....	16
Subtypes of Ovarian Cancer and Clinical Trial Recommendations .....	16
Treating 1 <sup>st</sup> Line.....	20
Treating Relapses.....	20
Maintenance.....	23
Genomics / Biomarkers.....	24
Pharmacotherapies (Alphabetical by Target).....	28
Angiogenesis inhibitors (VEGF / PDGF /FGF / VDA).....	28
Avastin; bevacizumab (Genentech).....	29
aflibercept; VEGF Trap (Sanofi-Aventis), .....	37
Nexavar; sorafenib (Bayer-Schering/Onyx), Sutent; sunitinib (Pfizer).....	37
Recentin; cediranib (AstraZeneca) .....	38
brivanib (Bristol-Myers Squibb).....	39
Votrient; pazopanib (GlaxoSmithKline).....	40
BIBF-1120 (Boehringer Ingelheim) .....	41
fosbretabulin; CA4P (OxiGene) .....	42
ASA404 (Novartis).....	42
AMG-386 (Amgen) .....	43
DLL4 / Notch.....	43
EGFR .....	44
Tarceva; erlotinib (OSI Pharmaceuticals / Genentech) .....	44
$\alpha$ -folate receptor inhibitors .....	45
Farletuzumab (Morphotek /Eisai).....	45
EC-145 (Endocyte) .....	46
Hedgehog Pathway Inhibitors.....	46
GDC-0449 (Genentech).....	46
IPI-504; cyclopamine (Infinity) .....	47
IGF-1 .....	47
Immunology Approaches.....	50
abagovomab (Menarini).....	50
MEK.....	51
AZD-6244; ARRY-142886 (AstraZeneca).....	51
miRNA (micro-RNA) .....	51
mTOR / PI3K / AKT.....	53
perifosine; KRX-0401 (Keryx) .....	56
Torisel; temsirolimus (Pfizer).....	56
Afinitor; everolimus (Novartis) .....	57

MK-2206 (Merck) / AZD-6244 (AstraZeneca) .....	59
AZD8055 (AstraZeneca) .....	60
PI3K .....	61
PARP.....	61
olaparib; AZD2281 (AstraZeneca) .....	66
BSI201 (BiPar Sciences / Sanofi-Aventis) .....	67
ABT-888 (Abbott) .....	70
MK-4827 (Merck), AG014699 (Pfizer).....	72
Platinum .....	72
cisplatin, carboplatin, Eloxatin; oxaliplatin .....	72
mitaplatin (Massachusetts Institute of Technology).....	73
Src .....	73
Sprycel; dasatinib (Bristol-Myers Squibb) .....	74
Superoxide .....	74
Yondelis; trabectedin (Ortho; Johnson & Johnson / Zeltia) .....	74
Taxane / Epothilone .....	76
Taxol; paclitaxel (Bristol-Myers Squibb).....	77
Abraxane (Abraxis).....	78
Xyotax; a.k.a. Opaxio (Cell Therapeutics) .....	78
patupilone (Novartis) .....	80
Thought Leader Interviews .....	81
Interview OHIID02387 .....	81
Interview OHIID02390 .....	90
Interview OHIID02389 .....	98
Interview OHIID02391 .....	108
Interview OHIID02392 .....	116
Interview OHIID02393 .....	126
Interview OHIID02394 .....	136